TargetMol

Azilsartan trimethylethanolamine

Product Code:
 
TAR-T30275
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T30275-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30275-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30275-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Azilsartan is an angiotensin II receptor antagonist for the treatment of hypertension and was developed by Takeda. Azilsartan Medoxomil lowers blood pressure by blocking the effects of angiotensin II, a type of vasopressin.
CAS:
1824707-75-6
Formula:
C30H33N5O6
Molecular Weight:
559.623
Purity:
0.98
SMILES:
C[N+](C)(C)CCO.CCOc1nc2cccc(C([O-])=O)c2n1Cc1ccc(cc1)-c1ccccc1-c1nc(=O)o[nH]1

References

1. Naruse M, Koike Y, Kamei N, Sakamoto R, Yambe Y, Arimitsu M. Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open-label, randomized clinical trial. PLoS One. 2019 Apr 3;14(4):e0214727. doi: 10.1371/journal.pone.0214727. eCollection 2019. PubMed PMID: 30943275; PubMed Central PMCID: PMC6447197. 2. Fukuda M, Isobe-Sasaki Y, Sato R, Miura T, Mizuno M, Ono M, Kiyono K, Yamamoto Y, Hayano J, Ohte N. The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers. J Renin Angiotensin Aldosterone Syst. 2019 Jan-Mar;20(1):1470320319839525. doi: 10.1177/1470320319839525. PubMed PMID: 30915878; PubMed Central PMCID: PMC6437324. 3. Li N, Fan L, Wu B, Dai G, Jiang C, Guo Y, Wang D. Preparation and in vitro/in vivo evaluation of azilsartan osmotic pump tablets based on the preformulation investigation. Drug Dev Ind Pharm. 2019 Mar 25:1-10. doi: 10.1080/03639045.2019.1593441. [Epub ahead of print] PubMed PMID: 30909753. 4. Hardin MD, Jacobs TF. Azilsartan. 2019 Mar 31. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK538473/ PubMed PMID: 30860708.